Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease (FIBROCHIR)
2026年6月5日 更新者：University Hospital, Bordeaux
Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of Chronic Obstructive Pulmonary Disease (COPD) and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.
The main objective of the study is to analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients with different stages of COPD compared to control subjects.
研究概览
地位
完全的
条件
研究类型
介入性
注册 (实际的)
50
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
-
Pessac、法国、33604
- University hospital of Bordeaux, Hôpital du Haut Lévêque
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
40年 及以上 (成人、年长者)
接受健康志愿者
不
研究人群
Controls and COPD patients will be recruited during surgical visit or hospitalization in thoracic surgery department before surgery.
描述
Inclusion Criteria:
- Male or female aged more than 40 yr
- Patient needed a thoracic surgery such as lobectomy for cancer or lung transplantation or lung reduction volume surgery.
- COPD group: diagnostic of COPD and differentiation of the stage from 1 to 4 according to the GOLD guidelines.
- Control group: subjects with normal lung function testing and no chronic symptoms (cough or expectoration). Subjects will be separated in 2 groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
- with a written informed consent
Exclusion Criteria:
- Subject without any social security or health insurance
- Asthma, lung fibrosis or idiopathic pulmonary hypertension
- Chronic viral infections (hepatitis, HIV)
- Pregnant woman or breastfeeding
- Subject included for cancer surgery with a Pn0 diagnosis not confirmed after the intervention.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：放映
- 分配：非随机化
- 介入模型：并行分配
- 屏蔽：单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：COPD
15 patients with COPD from 1 to 4 according to the GOLD 2011
|
analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients
|
|
安慰剂比较：Non smoker Control
15 patients without COPD and no smoking history
|
analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients
|
|
有源比较器：Smoker Control
15 patients without COPD but a smoking history
|
analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients
|
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Increased number of peri-bronchial and blood circulating fibrocytes gradually in each stages of COPD and compared to control subjects.
大体时间：Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)
|
Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Characterization of fibrocytes: expression of chemokines receptors, Toll Like Receptors, HLA class II
大体时间：Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)
|
Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)
|
|
Correlation between lung attenuation and the number of fibrocytes
大体时间：Assessed one year after inclusion visit (i.e. surgery date =Day 0)
|
Assessed one year after inclusion visit (i.e. surgery date =Day 0)
|
|
Correlation between plethysmography and the number of fibrocytes.
大体时间：Assessed one year after inclusion visit (i.e. surgery date = Day 0)
|
Assessed one year after inclusion visit (i.e. surgery date = Day 0)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 学习椅：Nicholas MOORE, MD-PhD、University Hospital, Bordeaux
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Henrot P, Beaufils F, Thumerel M, Eyraud E, Boudoussier A, Begueret H, Maurat E, Girodet PO, Marthan R, Berger P, Dupin I, Zysman M. Circulating fibrocytes as a new tool to predict lung cancer progression after surgery? Eur Respir J. 2021 Dec 9;58(6):2101221. doi: 10.1183/13993003.01221-2021. Print 2021 Dec. No abstract available.
- Dupin I, Thumerel M, Maurat E, Coste F, Eyraud E, Begueret H, Trian T, Montaudon M, Marthan R, Girodet PO, Berger P. Fibrocyte accumulation in the airway walls of COPD patients. Eur Respir J. 2019 Sep 5;54(3):1802173. doi: 10.1183/13993003.02173-2018. Print 2019 Sep.
- Eyraud E, Maurat E, Sac-Epee JM, Henrot P, Zysman M, Esteves P, Trian T, Dupuy JW, Leipold A, Saliba AE, Begueret H, Girodet PO, Thumerel M, Hustache-Castaing R, Marthan R, Levet F, Vallois P, Contin-Bordes C, Berger P, Dupin I. Short-range interactions between fibrocytes and CD8+ T cells in COPD bronchial inflammatory response. Elife. 2023 Jul 26;12:RP85875. doi: 10.7554/eLife.85875.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2013年4月10日
初级完成 (实际的)
2016年5月20日
研究完成 (实际的)
2016年5月20日
研究注册日期
首次提交
2012年9月17日
首先提交符合 QC 标准的
2012年9月20日
首次发布 (估计的)
2012年9月25日
研究记录更新
最后更新发布 (实际的)
2026年6月9日
上次提交的符合 QC 标准的更新
2026年6月5日
最后验证
2022年2月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CHUBX 2011/34
- 2012-A00571-42 (其他标识符：ANSM)
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.